FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123934071> ?p ?o ?g. }

• W3123934071 endingPage "251" @default.
• W3123934071 startingPage "240" @default.
• W3123934071 abstract "Dr. John Herrick described the first clinical case of sickle cell anaemia (SCA) in the United States in 1910. Subsequently, four decades later, Ingram and colleagues characterized the A to T substitution in DNA producing the GAG to GTG codon and replacement of glutamic acid with valine in the sixth position of the βS -globin chain. The establishment of Comprehensive Sickle Cell Centers in the United States in the 1970s was an important milestone in the development of treatment strategies and describing the natural history of sickle cell disease (SCD) comprised of genotypes including homozygous haemoglobin SS (HbSS), HbSβ0 thalassaemia, HbSC and HbSβ+ thalassaemia, among others. Early drug studies demonstrating effective treatments of HbSS and HbSβ0 thalassaemia, stimulated clinical trials to develop disease-specific therapies to induce fetal haemoglobin due to its ability to block HbS polymerization. Subsequently, hydroxycarbamide proved efficacious in adults with SCA and was Food and Drug Administration (FDA)-approved in 1998. After two decades of hydroxycarbamide use for SCD, there continues to be limited clinical acceptance of this chemotherapy drug, providing the impetus for investigators and pharmaceutical companies to develop non-chemotherapy agents. Investigative efforts to determine the role of events downstream of deoxy-HbS polymerization, such as endothelial cell activation, cellular adhesion, chronic inflammation, intravascular haemolysis and nitric oxide scavenging, have expanded drug targets which reverse the pathophysiology of SCD. After two decades of slow progress in the field, since 2018 three new drugs were FDA-approved for SCA, but research efforts to develop treatments continue. Currently over 30 treatment intervention trials are in progress to investigate a wide range of agents acting by complementary mechanisms, providing the rationale for ushering in the age of effective and safe combination drug therapy for SCD. Parallel efforts to develop curative therapies using haematopoietic stem cell transplant and gene therapy provide individuals with SCD multiple treatment options. We will discuss progress made towards drug development and potential combination drug therapy for SCD with the standard of care hydroxycarbamide." @default.
• W3123934071 created "2021-02-01" @default.
• W3123934071 creator A5046490615 @default.
• W3123934071 creator A5059999119 @default.
• W3123934071 creator A5086293556 @default.
• W3123934071 date "2021-01-20" @default.
• W3123934071 modified "2023-09-30" @default.
• W3123934071 title "Sickle cell disease: progress towards combination drug therapy" @default.
• W3123934071 cites W163413690 @default.
• W3123934071 cites W1719867626 @default.
• W3123934071 cites W1931426230 @default.
• W3123934071 cites W1966476720 @default.
• W3123934071 cites W1967520340 @default.
• W3123934071 cites W1977508606 @default.
• W3123934071 cites W1984789764 @default.
• W3123934071 cites W1986055602 @default.
• W3123934071 cites W1990599619 @default.
• W3123934071 cites W1994951969 @default.
• W3123934071 cites W1995325755 @default.
• W3123934071 cites W1996043889 @default.
• W3123934071 cites W1996778006 @default.
• W3123934071 cites W2001096364 @default.
• W3123934071 cites W2005898133 @default.
• W3123934071 cites W2006911199 @default.
• W3123934071 cites W2010907412 @default.
• W3123934071 cites W2016197401 @default.
• W3123934071 cites W2016237453 @default.
• W3123934071 cites W2019578579 @default.
• W3123934071 cites W2022529274 @default.
• W3123934071 cites W2026254409 @default.
• W3123934071 cites W2026498056 @default.
• W3123934071 cites W2026796607 @default.
• W3123934071 cites W2027277319 @default.
• W3123934071 cites W2027955104 @default.
• W3123934071 cites W2033380734 @default.
• W3123934071 cites W2037439664 @default.
• W3123934071 cites W2049129790 @default.
• W3123934071 cites W2053084472 @default.
• W3123934071 cites W2056010015 @default.
• W3123934071 cites W2061188498 @default.
• W3123934071 cites W2062318425 @default.
• W3123934071 cites W2064010033 @default.
• W3123934071 cites W2066173903 @default.
• W3123934071 cites W2080048112 @default.
• W3123934071 cites W2083399493 @default.
• W3123934071 cites W2083987270 @default.
• W3123934071 cites W2090159456 @default.
• W3123934071 cites W2091399084 @default.
• W3123934071 cites W2100360129 @default.
• W3123934071 cites W2111313654 @default.
• W3123934071 cites W2111444354 @default.
• W3123934071 cites W2111868926 @default.
• W3123934071 cites W2114229226 @default.
• W3123934071 cites W2118308240 @default.
• W3123934071 cites W2121087546 @default.
• W3123934071 cites W2138719823 @default.
• W3123934071 cites W2148547093 @default.
• W3123934071 cites W2153688565 @default.
• W3123934071 cites W2154412451 @default.
• W3123934071 cites W2161143576 @default.
• W3123934071 cites W2170482856 @default.
• W3123934071 cites W2181241483 @default.
• W3123934071 cites W2189616037 @default.
• W3123934071 cites W2266790363 @default.
• W3123934071 cites W2267505671 @default.
• W3123934071 cites W2274632826 @default.
• W3123934071 cites W2313541759 @default.
• W3123934071 cites W2325834386 @default.
• W3123934071 cites W2330023326 @default.
• W3123934071 cites W2330393631 @default.
• W3123934071 cites W2405628819 @default.
• W3123934071 cites W2465447473 @default.
• W3123934071 cites W2490064445 @default.
• W3123934071 cites W2511090954 @default.
• W3123934071 cites W2511966007 @default.
• W3123934071 cites W2524337537 @default.
• W3123934071 cites W2548177504 @default.
• W3123934071 cites W2559196229 @default.
• W3123934071 cites W2559643145 @default.
• W3123934071 cites W2593923181 @default.
• W3123934071 cites W2607337246 @default.
• W3123934071 cites W2610475181 @default.
• W3123934071 cites W2751645476 @default.
• W3123934071 cites W2755262585 @default.
• W3123934071 cites W2770033929 @default.
• W3123934071 cites W2797298193 @default.
• W3123934071 cites W2800078845 @default.
• W3123934071 cites W2800270039 @default.
• W3123934071 cites W2806007726 @default.
• W3123934071 cites W2883909188 @default.
• W3123934071 cites W2883955692 @default.
• W3123934071 cites W2889379121 @default.
• W3123934071 cites W2889666963 @default.
• W3123934071 cites W2897233669 @default.
• W3123934071 cites W2904449649 @default.
• W3123934071 cites W2911700566 @default.
• W3123934071 cites W2911725066 @default.
• W3123934071 cites W2941683499 @default.

• next